Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors
Ángel F. Álvarez-Prado, Roeltje R. Maas, Klara Soukup, Florian Klemm, Mara Kornete, Fanny S. Krebs, Vincent Zoete, Sabina Berezowska, Jean‐Philippe Brouland, Andreas F. Hottinger, Roy Thomas Daniel, Monika E. Hegi, Johanna A. Joyce
Abstract
Brain metastases (BrMs) are the most common form of brain tumors in adults and frequently originate from lung and breast primary cancers. BrMs are associated with high mortality, emphasizing the need for more effective therapies. Genetic profiling of primary tumors is increasingly used as part of the effort to guide targeted therapies against BrMs, and immune-based strategies for the treatment of metastatic cancer are gaining momentum. However, the tumor immune microenvironment (TIME) of BrM is extremely heterogeneous, and whether specific genetic profiles are associated with distinct immune states remains unknown. Here, we perform an extensive characterization of the immunogenomic landscape of human BrMs by combining whole-exome/whole-genome sequencing, RNA sequencing of immune cell populations, flow cytometry, immunofluorescence staining, and tissue imaging analyses. This revealed unique TIME phenotypes in genetically distinct lung- and breast-BrMs, thereby enabling the development of personalized immunotherapies tailored by the genetic makeup of the tumors.